Skip to main content
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
271.47
+5.13 (1.93%)
At close: Jun 26, 2026, 4:00 PM EDT
272.70
+1.23 (0.45%)
After-hours: Jun 26, 2026, 7:31 PM EDT

Labcorp Holdings Revenue by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
11.01B 10.88B 10.74B 10.52B 10.30B 10.15B 9.91B 9.70B
Diagnostics Growth
6.92% 7.19% 8.43% 8.53% 8.26% 7.82% 5.91% 5.22%
Drug Development
3.16B 3.10B 3.07B 3.01B 2.93B 2.92B 2.85B 2.83B
Drug Development Growth
7.65% 6.01% 7.78% 6.32% 3.87% -16.80% -32.26% -42.15%

Operating Income by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.81B 1.78B 1.72B 1.66B 1.62B 1.61B 1.60B 1.60B
Diagnostics Growth
12.08% 10.81% 7.48% 3.61% 3.08% 0.95% -1.48% -4.68%
Drug Development
512.30M 498.50M 493.20M 481.90M 466.00M 459.00M 437.20M 425.30M
Drug Development Growth
9.94% 8.61% 12.81% 13.31% 10.30% 2.80% -19.93% -34.34%
General Corporate Expenses
-282.90M -276.80M -276.30M -274.20M -268.70M -268.30M -269.00M -273.20M

Operating Expense Breakdown
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.22B 2.22B 2.27B 2.29B 2.27B 2.23B 2.17B 2.12B
Selling, General, and Administrative Growth
-2.04% -0.61% 4.85% 7.74% 9.41% 5.30% 2.18% 0.89%
Amortization
286.00M 280.00M 277.80M 272.00M 265.90M 256.40M 245.20M 237.20M
Amortization Growth
7.56% 9.20% 13.30% 14.67% 17.40% 8.78% 3.42% -3.81%
Restructuring and Other
127.20M 127.20M 27.80M 39.90M 47.40M 46.00M 52.90M 42.40M
Restructuring and Other Growth
168.35% 176.52% -47.45% -5.90% 1.72% -8.37% 21.33% -17.19%
Impairments
4.30M 4.30M 3.50M 2.80M 2.80M 5.30M 336.30M 346.50M
Impairments Growth
53.57% -18.87% -98.96% -99.19% -99.20% -98.48% 17.79% 25.86%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.